Reserpine

Pricing Availability   Qty
Description: Inhibitor of vesicular monoamine transport
Chemical Name: (3β,16β,17α,18β,20α)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
Purity: ≥99% (HPLC)
Datasheet
Citations (4)
Reviews (1)
Literature (2)

Biological Activity for Reserpine

Binds the vesicular monoamine transporter (VMAT2) and inhibits transport of biogenic amines into adrenal chromaffin granules and synaptic vesicles. Causes depletion of biogenic amine stores. Antihypertensive and antipsychotic.

Technical Data for Reserpine

M. Wt 608.68
Formula C33H40N2O9
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 50-55-5
PubChem ID 5770
InChI Key QEVHRUUCFGRFIF-MDEJGZGSSA-N
Smiles [H][C@@](N4CC3)(C[C@@]([C@H]([C@@](OC)=O)[C@@H](OC)[C@H](OC(C6=CC(OC)=C(OC)C(OC)=C6)=O)C5)([H])[C@@]5([H])C4)C2=C3C1=C(N2)C=C(OC)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Reserpine

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 6.09 10

Preparing Stock Solutions for Reserpine

The following data is based on the product molecular weight 608.68. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 16.43 mL 82.14 mL 164.29 mL
0.5 mM 3.29 mL 16.43 mL 32.86 mL
1 mM 1.64 mL 8.21 mL 16.43 mL
5 mM 0.33 mL 1.64 mL 3.29 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Reserpine

Certificate of Analysis / Product Datasheet
Select another batch:

References for Reserpine

References are publications that support the biological activity of the product.

Schuldiner et al (1993) Reserpine binding to a vesicular amine transporter expressed in chinese hamster ovary fibroblasts. J.Biol.Chem. 268 29 PMID: 8416935

Heslop and Curzon (1999) Effect of rese. on behavioural responses to agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes. Neuropharmacology 38 883 PMID: 10465692

Metzger et al (2002) Inhibitory effect of rese. on DA transporter function. Eur.J.Pharmacol. 456 39 PMID: 12450567


If you know of a relevant reference for Reserpine, please let us know.

View Related Products by Product Action

View all Vesicular Monoamine Transporter Inhibitors

Keywords: Reserpine, Reserpine supplier, inhibitors, inhibits, vesicular, monoamine, transporters, Noradrenalin, NET, Adrenergic, Transporters, Monoamine, Neurotransmitter, DAT, Dopamine, Serotonin, SERT, 5-HT, reuptake, 5-Hydroxytryptamine, VMAT2, noradrenaline, Vesicular, 2742, Tocris Bioscience

⚠ WARNING: This product can expose you to chemicals including Reserpine, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov

4 Citations for Reserpine

Citations are publications that use Tocris products. Selected citations for Reserpine include:

Njagi et al (2010) Electrochemical quantification of serotonin in the live embryonic zebrafish intestine. Anal Chem 82 1822 PMID: 20148518

Prado et al (2012) Stimulation of DA receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. Cell Tissue Res 188 3062 PMID: 22379034

Berrios et al (2016) Loss of UBE3A from TH-expressing neurons suppresses GABA co-release and enhances VTA-NAc optical self-stimulation. Neuropsychopharmacology 7 10702 PMID: 26869263

Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. J Immunol 40 766 PMID: 25249058


Do you know of a great paper that uses Reserpine from Tocris? Please let us know.

Reviews for Reserpine

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Reserpine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Reserpine as a VMAT bloker to depleted the endogenous DA in mouse striatum.
By Benoit Delignat-Lavaud on 01/04/2018
Assay Type: Ex Vivo
Species: Mouse
Cell Line/Tissue: striatum slices

This product work super fine in electrophysiology for blocking the VMAT. We currently use it at the concentration of 5 µM in normal ACSF.


Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.